VCM
SPRY icon

Versant Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Versant Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.94K Sell
991
-547
-36% -$4.71K ﹤0.01% 2303
2026
Q1 		$12.3K Sell
1,538
-1,036
-40% -$9.93K ﹤0.01% 2046
2025
Q4 		$30K Buy
2,574
+1,231
+92% +$12K ﹤0.01% 1387
2025
Q3 		$13.5K Buy
1,343
+721
+116% +$10.3K ﹤0.01% 1796
2025
Q2 		$10.9K Hold
622
– – ﹤0.01% 1855
2025
Q1 		$7.83K Buy
+622
New +$7.48K ﹤0.01% 1842

Other funds holding SPRY

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Versant Capital Management's SPRY Position: Q2 2026 in Review

Versant Capital Management reduced its ARS Pharmaceuticals (SPRY) stake by 36% in Q2 2026, selling an estimated $4.71K and leaving 991 shares worth $7.94K. The position accounts for ﹤0.01% of the portfolio, ranked #2303.

Versant Capital Management first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $30K in Q4 2025. 17 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Versant Capital Management held 991 shares of ARS Pharmaceuticals worth $7.94K as of Q2 2026.
  • Versant Capital Management sold 547 ARS Pharmaceuticals shares in Q2 2026, an estimated $4.71K.
  • ARS Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2303 holding.
  • Versant Capital Management first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Versant Capital Management's ARS Pharmaceuticals position peaked at $30K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.